Biomarkers and Targets for Lung Immunotherapy in NSCLC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter study aims to identify biomarkers in blood and tumor tissue that predict response to immunotherapy in advanced non-small cell lung cancer. Researchers will collect blood and tumor samples at enrollment and again at progression, to compare markers over time and between early and late disease. The study will also explore the HVEM/BTLA pathway as a potential mechanism influencing treatment effectiveness. About 200 patients will be enrolled across two institutions over up to seven years. The findings could help tailor immunotherapy for lung cancer patients based on biomarker profiles.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged 18 years or older, male or female.
* Willing to participate in the study and having signed a written informed consent form.
* Presenting a strong suspicion of localized resectable or advanced unresectable non-small cell lung cancer, or having a histologically confirmed non-small cell lung cancer.
* Affiliated with a social security system or benefiting from such a system.

Exclusion Criteria:

* Individuals in an emergency situation, adults under legal protection (guardianship, curatorship, or judicial protection), or individuals unable to provide informed consent.
* Inability to comply with the medical follow-up required by the study for geographical, social, or psychological reasons.
* History of solid organ transplantation or hematopoietic stem cell transplantation.
* Pregnant or breastfeeding women.

Where it's running

• Rochigneux
  Marseille, Institut Paoli Calmettes, France Recruiting

Study contacts

• Study coordinator: Jihane pakradouni
• Email: pakradounij@ipc.unicancer.fr
• Phone: 0491223824

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.